A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
2020-07-04
عنوان الدراسة
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
داعم الدراسة
Abbvie Biopharmaceuticals GmbH / KSU Liver Disease Research Center
دواء الدراسة
ombitasvir \ paritaprevir \ ritonavir
رقم بروتوكول الدراسة
Version 1.3.1
حالة الدراسة
Ongoing
موقع الدراسة
King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.